dgn-np:NP49293.RAgdmcAMWIXXE5gNfbsGYY2c8_W_d58sjcLHmytOiZygg130_provenance {
  dgn-np:NP49293.RAgdmcAMWIXXE5gNfbsGYY2c8_W_d58sjcLHmytOiZygg130_assertion dcterms:description "[Both preventive (from Day 0 to Day 18) and therapeutic (from Day 7 to Day 18 or from Day 9 to Day 19) VPA (500 mg/kg, intra-gastric) administration to EAE rats once daily greatly reduced the severity and duration of EAE, and suppressed mRNA levels of interferon-I3 (IFN-I3), tumor necrosis factor-I+- (TNF-I+-), interleukin-1I2 (IL-1I2) and IL-17, matrix metalloproteinase 9 (MMP9), inducible nitric oxide synthase (iNOS) and transcription factor T-bet, but increased levels of IL-4 mRNA in EAE spinal cords.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ;
    wi:evidence dgn-void:source_evidence_predicted ;
    sio:SIO_000772 miriam-pubmed:22800566 ;
    prov:wasDerivedFrom dgn-void:rgd-20150221 ;
    prov:wasGeneratedBy eco:ECO_0000218 .
  dgn-void:rgd-20150221 pav:importedOn "2015-02-21"^^xsd:date .
  dgn-void:source_evidence_predicted a eco:ECO_0000266 ;
    rdfs:comment "Gene-disease associations inferred from animal model manually asserted gene-disease associations."@en ;
    rdfs:label "DisGeNET evidence - PREDICTED"@en .
}